Myriad wins US patent for p19 gene:
This article was originally published in Clinica
Executive Summary
Myriad Genetics has received a US patent covering the DNA sequence of the tumour suppressor gene p19, otherwise known as MTS2. The patent also covers primers, probes and vectors relating to the use of the p19 gene in diagnostic and therapeutic products. The p19 gene is an important regulator of the p53 cancer pathway, said the Salt Lake City, Utah-based company. p53, the most common tumour suppressor gene, is mutated in over half of all types of cancer.